Atacicept for IgA Nephropathy: PDUFA 7 July 2026 Among the most closely watched remaining FDA drug approval decisions in July 2026 is atacicept (Vera Therapeutics), a recombinant fusion protein targeting both BAFF and APRIL, two cytokines central to the pathogenesis of immunoglobulin A nephropathy (IgAN)
RXR agonists are also effective in the treatment of some neuropathies, such as Alzheimers disease 61 and Parkinsons disease in animal models 62
Xu, B., Kong, X., Xu, R., Song, Y., Liu, L., Zhou, Z., Gu, R., Shi, X., Zhao, M., Huang, X., He, M., Fu, J., Cai, Y., Li, P., Cheng, X., Wu, C., Chen, F., Zhang, Y., Tang, G., Huo, Y
In one 10 ml scoop, it provides a high dose of 2200 mg of L-carnitine
10.1016/j.neuroscience.2014.11.025 26
GH is necessary for maintaining skeletal muscle health, promoting tissue healing, and facilitating all anabolic processes